Rare bleeding disorders: Diagnosis and treatment

Roberta Palla, Flora Peyvandi, Amy D. Shapiro

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Despite the worldwide prevalence of rare bleeding disorders (RBDs), knowledge of these conditions and their management is suboptimal; health care professionals often have little diagnostic and treatment experience with variable access to diagnostic modalities required for accurate identification. Therefore, patients often experience morbidity and mortality due to delayed diagnosis. As RBDs represent a small potential commercial market, few, if any, specific therapies exist for these conditions. As a result, affected individuals commonly face delayed diagnosis, incomplete laboratory evaluation, and limited treatment options. Standardization and customization of coagulation assays, full genome sequencing, and global clotting assays will significantly improve diagnosis of patients with RBDs. In addition, new therapeutic modalities, both recombinant and plasma derived, are emerging, at least in developed countries. Registries and clinical trials have demonstrated decreased bleeding and improved outcomes when patients are appropriately diagnosed and properly treated. Expansion and harmonization of international registries has been initiated to correlate genotype, laboratory, and clinical phenotypes including bleeding severity to improve the diagnosis and therapeutic approach. This review focuses on the latest advances in our understanding, diagnosis, and treatment of RBDs. ( Blood. 2015; 125(13):2052-2061)

Original languageEnglish
Pages (from-to)2052-2061
Number of pages10
JournalBlood
Volume125
Issue number13
DOIs
Publication statusPublished - Mar 26 2015

Fingerprint

Hemorrhage
Delayed Diagnosis
Assays
Registries
Therapeutics
Coagulation
Health care
Standardization
Blood
Genes
Developing Countries
Plasmas
Genotype
Clinical Trials
Genome
Morbidity
Delivery of Health Care
Phenotype
Mortality

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology
  • Medicine(all)

Cite this

Rare bleeding disorders : Diagnosis and treatment. / Palla, Roberta; Peyvandi, Flora; Shapiro, Amy D.

In: Blood, Vol. 125, No. 13, 26.03.2015, p. 2052-2061.

Research output: Contribution to journalArticle

Palla, Roberta ; Peyvandi, Flora ; Shapiro, Amy D. / Rare bleeding disorders : Diagnosis and treatment. In: Blood. 2015 ; Vol. 125, No. 13. pp. 2052-2061.
@article{249ee53acd364e8ebefa2eb661087181,
title = "Rare bleeding disorders: Diagnosis and treatment",
abstract = "Despite the worldwide prevalence of rare bleeding disorders (RBDs), knowledge of these conditions and their management is suboptimal; health care professionals often have little diagnostic and treatment experience with variable access to diagnostic modalities required for accurate identification. Therefore, patients often experience morbidity and mortality due to delayed diagnosis. As RBDs represent a small potential commercial market, few, if any, specific therapies exist for these conditions. As a result, affected individuals commonly face delayed diagnosis, incomplete laboratory evaluation, and limited treatment options. Standardization and customization of coagulation assays, full genome sequencing, and global clotting assays will significantly improve diagnosis of patients with RBDs. In addition, new therapeutic modalities, both recombinant and plasma derived, are emerging, at least in developed countries. Registries and clinical trials have demonstrated decreased bleeding and improved outcomes when patients are appropriately diagnosed and properly treated. Expansion and harmonization of international registries has been initiated to correlate genotype, laboratory, and clinical phenotypes including bleeding severity to improve the diagnosis and therapeutic approach. This review focuses on the latest advances in our understanding, diagnosis, and treatment of RBDs. ( Blood. 2015; 125(13):2052-2061)",
author = "Roberta Palla and Flora Peyvandi and Shapiro, {Amy D.}",
year = "2015",
month = "3",
day = "26",
doi = "10.1182/blood-2014-08-532820",
language = "English",
volume = "125",
pages = "2052--2061",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - Rare bleeding disorders

T2 - Diagnosis and treatment

AU - Palla, Roberta

AU - Peyvandi, Flora

AU - Shapiro, Amy D.

PY - 2015/3/26

Y1 - 2015/3/26

N2 - Despite the worldwide prevalence of rare bleeding disorders (RBDs), knowledge of these conditions and their management is suboptimal; health care professionals often have little diagnostic and treatment experience with variable access to diagnostic modalities required for accurate identification. Therefore, patients often experience morbidity and mortality due to delayed diagnosis. As RBDs represent a small potential commercial market, few, if any, specific therapies exist for these conditions. As a result, affected individuals commonly face delayed diagnosis, incomplete laboratory evaluation, and limited treatment options. Standardization and customization of coagulation assays, full genome sequencing, and global clotting assays will significantly improve diagnosis of patients with RBDs. In addition, new therapeutic modalities, both recombinant and plasma derived, are emerging, at least in developed countries. Registries and clinical trials have demonstrated decreased bleeding and improved outcomes when patients are appropriately diagnosed and properly treated. Expansion and harmonization of international registries has been initiated to correlate genotype, laboratory, and clinical phenotypes including bleeding severity to improve the diagnosis and therapeutic approach. This review focuses on the latest advances in our understanding, diagnosis, and treatment of RBDs. ( Blood. 2015; 125(13):2052-2061)

AB - Despite the worldwide prevalence of rare bleeding disorders (RBDs), knowledge of these conditions and their management is suboptimal; health care professionals often have little diagnostic and treatment experience with variable access to diagnostic modalities required for accurate identification. Therefore, patients often experience morbidity and mortality due to delayed diagnosis. As RBDs represent a small potential commercial market, few, if any, specific therapies exist for these conditions. As a result, affected individuals commonly face delayed diagnosis, incomplete laboratory evaluation, and limited treatment options. Standardization and customization of coagulation assays, full genome sequencing, and global clotting assays will significantly improve diagnosis of patients with RBDs. In addition, new therapeutic modalities, both recombinant and plasma derived, are emerging, at least in developed countries. Registries and clinical trials have demonstrated decreased bleeding and improved outcomes when patients are appropriately diagnosed and properly treated. Expansion and harmonization of international registries has been initiated to correlate genotype, laboratory, and clinical phenotypes including bleeding severity to improve the diagnosis and therapeutic approach. This review focuses on the latest advances in our understanding, diagnosis, and treatment of RBDs. ( Blood. 2015; 125(13):2052-2061)

UR - http://www.scopus.com/inward/record.url?scp=84926150235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926150235&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-08-532820

DO - 10.1182/blood-2014-08-532820

M3 - Article

C2 - 25712993

AN - SCOPUS:84926150235

VL - 125

SP - 2052

EP - 2061

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -